These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Galat A; Rosso J; Guellich A; Van Der Gucht A; Rappeneau S; Bodez D; Guendouz S; Tissot CM; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Itti E; Meignan M; Damy T Amyloid; 2015; 22(4):210-20. PubMed ID: 26465835 [TBL] [Abstract][Full Text] [Related]
9. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993 [TBL] [Abstract][Full Text] [Related]
10. Apical sparing pattern of left ventricular myocardial Van Der Gucht A; Cottereau AS; Abulizi M; Guellich A; Blanc-Durand P; Israel JM; Galat A; Plante-Bordeneuve V; Dubois-Randé JL; Bodez D; Rosso J; Damy T; Itti E J Nucl Cardiol; 2018 Dec; 25(6):2072-2079. PubMed ID: 28447284 [TBL] [Abstract][Full Text] [Related]
11. Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure? Jonker DL; Hazenberg BPC; Nienhuis HLA; Slart RHJA; Glaudemans AWJM; Noordzij W J Nucl Cardiol; 2020 Oct; 27(5):1774-1784. PubMed ID: 30374850 [TBL] [Abstract][Full Text] [Related]
12. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis. Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. Cappelli F; Gallini C; Di Mario C; Costanzo EN; Vaggelli L; Tutino F; Ciaccio A; Bartolini S; Angelotti P; Frusconi S; Farsetti S; Vergaro G; Giorgetti A; Marzullo P; Genovesi D; Emdin M; Perfetto F J Nucl Cardiol; 2019 Apr; 26(2):497-504. PubMed ID: 28537040 [TBL] [Abstract][Full Text] [Related]
14. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report. Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273 [TBL] [Abstract][Full Text] [Related]
15. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction. Chen W; Ton VK; Dilsizian V Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480 [TBL] [Abstract][Full Text] [Related]
16. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. Singh V; Falk R; Di Carli MF; Kijewski M; Rapezzi C; Dorbala S J Nucl Cardiol; 2019 Feb; 26(1):158-173. PubMed ID: 30569412 [TBL] [Abstract][Full Text] [Related]
17. Cardiac scintigraphy with de Haro-Del Moral FJ; Pubul-Núñez V; Casáns-Tormo I; Jiménez-Heffernan A; Ruano-Pérez R Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):254-266. PubMed ID: 32513587 [TBL] [Abstract][Full Text] [Related]
20. A challenging road to diagnosing transthyretin cardiac amyloidosis and using technetium-99m pyrophosphate bone scintigraphy in nuclear cardiology - A case report. Kavita A; Abdul Onny MA; Suppiah S; Abdul Aziz AF; Hashim H; Raja Shariff RE; Ng CS Med J Malaysia; 2021 Sep; 76(5):762-767. PubMed ID: 34508392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]